| dc.contributor.author |
Mittal, Anupama |
|
| dc.contributor.author |
Chitkara, Deepak |
|
| dc.date.accessioned |
2024-01-05T09:16:22Z |
|
| dc.date.available |
2024-01-05T09:16:22Z |
|
| dc.date.issued |
2020-09 |
|
| dc.identifier.uri |
https://www.future-science.com/doi/abs/10.4155/tde-2020-0088 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13683 |
|
| dc.description.abstract |
To overcome problems associated with current conventional formulations of DTX, efforts have been made to develop a variety of DTX-loaded nanosystems. These systems have improved water solubility, bioavailability and antitumor efficacy with a specific accumulation of drugs at tumor sites. Some of the novel DTX nanoformulations, which demonstrated exciting in vivo anticancer efficacy results, have grabbed the attention of pharmaceutical companies and successfully entered clinical trials |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Future Science Group |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Cancer |
en_US |
| dc.subject |
Conventional formulations |
en_US |
| dc.subject |
Nano-carriers |
en_US |
| dc.subject |
Efficacy |
en_US |
| dc.title |
Docetaxel and its nanoformulations: how delivery strategies could impact the therapeutic outcome? |
en_US |
| dc.type |
Article |
en_US |